|
US2021052684A1
|
|
Methods, compositions, and kits addressing depressed mood
|
|
WO2020237379A1
|
|
Predictive markers of brain inflammation
|
|
WO2020222041A1
|
|
Methods and compounds using in-loop fluorination
|
|
WO2020178782A1
|
|
Modulators of ampa receptor signaling
|
|
WO2020165802A1
|
|
Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
|
|
US2020168317A1
|
|
Tool for assisting individuals experiencing auditory hallucinations to differentiate between hallucinations and ambient sounds
|
|
CA3019970A1
|
|
Methods for diagnosing or treating post-traumatic stress disorder, and compositions therefor
|
|
US2020066406A1
|
|
Tool for identifying occurrence of acute incident symptomatic of mental condition or disorder
|
|
US2018303892A1
|
|
Methods and compositions addressing depressed mood
|
|
CA3054093A1
|
|
A cell-based assay and kits for assessing serum anticholinergic activity
|
|
WO2018137028A1
|
|
Methods, compositions and kits for assessing brain inflammation in depression and related conditions
|
|
CA2950616A1
|
|
Brain temporal complexity in explaining the therapeutic and cognitive effects of seizure therapy
|
|
US2018267015A1
|
|
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
US2017226559A1
|
|
Markers for mood disorders
|
|
EP3154542A1
|
|
Methods and compositions addressing depressed mood
|
|
CA2891830A1
|
|
Genetic markers for suicide risk and related methods
|
|
SG11201607137WA
|
|
Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
|
|
CN106062213A
|
|
Genetic markers associated with suicide risk and methods of use thereof
|
|
WO2015054792A1
|
|
Genetic markers for antipsychotic induced weight gain and methods for use thereof
|
|
US2014378387A1
|
|
Compositions and methods for treating multiple sclerosis
|
